SCYNEXIS INC (SCYX) Stock Price, Forecast & Analysis
USA - NASDAQ:SCYX - US8112922005 - Common Stock
SCYX Key Statistics, Chart & Performance
The current stock price of SCYX is 0.595 USD. In the past month the price decreased by -22.73%. In the past year, price decreased by -54.58%.
SCYX Latest News, Press Relases and Analysis
SCYX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.78 | 3.97B |
Related stock screener links
About SCYX
Company Profile
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 28 full-time employees. The company went IPO on 2014-05-02. The company is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. The company is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
Company Info
SCYNEXIS INC
1 Evertrust Plaza, 13th Floor
Jersey City NEW JERSEY 07302 US
CEO: Marco Taglietti
Employees: 28
Phone: 12018845485
SCYNEXIS INC / SCYX FAQ
Can you describe the business of SCYNEXIS INC?
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 28 full-time employees. The company went IPO on 2014-05-02. The company is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. The company is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
What is the stock price of SCYNEXIS INC today?
The current stock price of SCYX is 0.595 USD. The price decreased by -0.23% in the last trading session.
Does SCYX stock pay dividends?
SCYX does not pay a dividend.
How is the ChartMill rating for SCYNEXIS INC?
SCYX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does SCYNEXIS INC belong to?
SCYNEXIS INC (SCYX) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for SCYX stock?
SCYNEXIS INC (SCYX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
What is SCYNEXIS INC worth?
SCYNEXIS INC (SCYX) has a market capitalization of 24.94M USD. This makes SCYX a Nano Cap stock.
SCYX Technical Analysis
SCYX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SCYX. The financial health of SCYX is average, but there are quite some concerns on its profitability.
SCYX Financial Highlights
Over the last trailing twelve months SCYX reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 31.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.16% | ||
| ROE | -43.89% | ||
| Debt/Equity | 0 |
SCYX Forecast & Estimates
9 analysts have analysed SCYX and the average price target is 3.74 USD. This implies a price increase of 528.58% is expected in the next year compared to the current price of 0.595.
For the next year, analysts expect an EPS growth of 8.43% and a revenue growth 32.74% for SCYX